<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7044319\results\search\tropicalVirus\results.xml">
  <result pre=": Article Complete Protection in Macaques Conferred by Purified Inactivated" exact="Zika" post="Vaccine: Defining a Correlate of Protection YoungGingerginger.young@takeda.com1BohningKelly J.1Zahralban-SteeleMelissa1HatherGreg2TadepalliSambasivarao3MickeyKristen4GodinC. Steven5SanisettySrisowmya1SonnbergStephanie1PatelHetal"/>
  <result pre="http://creativecommons.org/licenses/by/4.0/. Abstract A critical global health need exists for a" exact="Zika" post="vaccine capable of mitigating the effects of future Zika"/>
  <result pre="a Zika vaccine capable of mitigating the effects of future" exact="Zika" post="epidemics. In this study we evaluated the antibody responses"/>
  <result pre="responses and efficacy of an aluminum hydroxide adjuvanted purified inactivated" exact="Zika" post="vaccine (PIZV) against challenge with Zika virus (ZIKV) strain"/>
  <result pre="hydroxide adjuvanted purified inactivated Zika vaccine (PIZV) against challenge with" exact="Zika" post="virus (ZIKV) strain PRVABC59. Indian rhesus macaques received two"/>
  <result pre="ranging from 0.016 µg − 10 µg and were subsequently challenged with" exact="ZIKV" post="six weeks or one year following the second immunization."/>
  <result pre="that was boosted by a second immunization. Complete protection against" exact="ZIKV" post="infection was achieved with the higher PIZV doses of"/>
  <result pre="Vaccines, Inc. Introduction In 2015 and 2016, large outbreaks of" exact="Zika" post="virus (ZIKV) occurred in the Americas. These outbreaks were"/>
  <result pre="of 7 infants born to pregnant women with laboratory confirmed" exact="Zika" post="in the US and US territories1. Incidence of ZIKV"/>
  <result pre="confirmed Zika in the US and US territories1. Incidence of" exact="ZIKV" post="infections subsequently declined in most of the Americas throughout"/>
  <result pre="Americas throughout 2017 and 20182. With the sporadic nature of" exact="ZIKV" post="outbreaks and a very low incidence of symptomatic disease"/>
  <result pre="in pregnant women demonstrate that the need for an effective" exact="Zika" post="vaccine remains. In such circumstances, alternative regulatory strategies such"/>
  <result pre="licensure3. Non-human primate studies have contributed to the development of" exact="ZIKV" post="vaccines by demonstrating protective efficacy and identifying biomarkers of"/>
  <result pre="that is reasonably likely to predict clinical benefit of several" exact="ZIKV" post="vaccines4,5. Indian rhesus macaques (Macaca mulatta) are susceptible to"/>
  <result pre="ZIKV vaccines4,5. Indian rhesus macaques (Macaca mulatta) are susceptible to" exact="ZIKV" post="infection and have been used extensively as a model"/>
  <result pre="been used extensively as a model to study efficacy of" exact="ZIKV" post="vaccines and pathogenesis of multiple ZIKV isolates6–10. ZIKV infection"/>
  <result pre="to study efficacy of ZIKV vaccines and pathogenesis of multiple" exact="ZIKV" post="isolates6–10. ZIKV infection can be performed by subcutaneous injection,"/>
  <result pre="efficacy of ZIKV vaccines and pathogenesis of multiple ZIKV isolates6–10." exact="ZIKV" post="infection can be performed by subcutaneous injection, which mimics"/>
  <result pre="via mosquito bite and causes consistent viremia11–15. The kinetics of" exact="ZIKV" post="infection are similar in rhesus macaques and humans where"/>
  <result pre="of infection and resolves within 10–14 days10,13,14. The purified inactivated" exact="Zika" post="vaccine (PIZV) has previously been evaluated in mouse models"/>
  <result pre="AG129 and CD1 mice and protected AG129 mice against lethal" exact="ZIKV" post="challenge16. In those studies, Baldwin et al. demonstrated that"/>
  <result pre="further evaluate immunogenicity and efficacy of PIZV, we conducted three" exact="ZIKV" post="challenge studies in rhesus macaques. In the first study,"/>
  <result pre="dose selection We conducted a challenge study to select a" exact="ZIKV" post="challenge dose that appropriately mimics human infection in Indian"/>
  <result pre="104 focus forming units (ffu; n = 2) or 105 ffu (n = 2)" exact="ZIKV" post="PRVABC59. Serum was collected daily for ZIKV RNA analysis"/>
  <result pre="105 ffu (n = 2) ZIKV PRVABC59. Serum was collected daily for" exact="ZIKV" post="RNA analysis by real-time quantitative RT-PCR (RT-qPCR), on days"/>
  <result pre="post-infection (dpi), and every other day from day 13–21 dpi." exact="Zika" post="viral RNA (vRNA) was detected above the assay lower"/>
  <result pre="of 4.8 and 5.0 log10 copies/mL, both on day 4." exact="Zika" post="vRNA was not detected above the assay LLOQ in"/>
  <result pre="vRNA per challenge dose and day post-challenge. Challenge Dose (ffu)" exact="Zika" post="vRNA (log10 copies/mL) Day 1 Day 2 Day 3"/>
  <result pre="UD UD UD 3.8 4.3 5.0 5.0 4.0 UD UD" exact="Zika" post="vRNA (log10 copies/mL) per day post-challenge for each individual"/>
  <result pre="vRNA (log10 copies/mL) per day post-challenge for each individual macaque." exact="Zika" post="vRNA for individual macaques was not quantified in the"/>
  <result pre="on day 71. Serum neutralizing antibodies were tested using a" exact="Zika" post="reporter virus particle (RVP) assay. All macaques were seronegative"/>
  <result pre="on day 1 and control macaques remained seronegative prior to" exact="ZIKV" post="challenge (Fig. 1). Twenty-eight days following the first vaccine"/>
  <result pre="(p = 0.037) compared to the 0.4 µg dose group. Titers prior to" exact="ZIKV" post="challenge on day 71 were slightly decreased compared to"/>
  <result pre="the level of neutralizing antibody was comparable to infection with" exact="ZIKV" post="challenge in the placebo group. The lack of anamnestic"/>
  <result pre="2, and 10 µg PIZV dose groups suggests that infection by" exact="ZIKV" post="challenge virus may have been prevented by vaccination. Figure"/>
  <result pre="vaccination. Figure 1 Neutralizing antibody titers following PIZV vaccination and" exact="ZIKV" post="challenge. Rhesus macaques were vaccinated on days 1 and"/>
  <result pre="days 1 and 29 and challenged on day 71. Individual" exact="Zika" post="RVP titers for each vaccine group on study day"/>
  <result pre="day 57 (28 days post-second dose), day 71 (prior to" exact="ZIKV" post="challenge), and day 101 (30 days post-ZIKV challenge). Mean"/>
  <result pre="anti-Zika IgG was detected in the control group prior to" exact="ZIKV" post="challenge. PIZV elicited dose-dependent anti-Zika IgG responses (Fig. 2)"/>
  <result pre="PIZV dose for all vaccinated groups (all p-values ≤0.001). Following" exact="ZIKV" post="challenge, the anti-Zika IgG responses increased significantly in the"/>
  <result pre="day 57 (28 days post-second dose), day 71 (prior to" exact="ZIKV" post="challenge), and day 101 (30 days post-ZIKV challenge). Mean"/>
  <result pre="shown for all groups and time points. PIZV protects against" exact="ZIKV" post="challenge Rhesus macaques were challenged subcutaneously on day 71"/>
  <result pre="the 0.4, 2, or 10 µg PIZV dose were protected against" exact="ZIKV" post="challenge, as no Zika vRNA could be quantified in"/>
  <result pre="10 µg PIZV dose were protected against ZIKV challenge, as no" exact="Zika" post="vRNA could be quantified in any of the macaques"/>
  <result pre="be quantified in any of the macaques in these groups." exact="Zika" post="vRNA was quantified in 3/6 macaques receiving the 0.08 µg"/>
  <result pre="macaques in the control group (Fig. 3). The peak post-challenge" exact="Zika" post="vRNA level decreased with increasing vaccine dose level. The"/>
  <result pre="vRNA level decreased with increasing vaccine dose level. The peak" exact="Zika" post="vRNA occurred on day 74 (3 days post-challenge), with"/>
  <result pre="challenge virus were seen throughout the studies. Figure 3 Post-challenge" exact="Zika" post="vRNA per group and study day. Zika vRNA (log10"/>
  <result pre="Figure 3 Post-challenge Zika vRNA per group and study day." exact="Zika" post="vRNA (log10 copies/mL) post-ZIKV challenge. Each line represents an"/>
  <result pre="(log10 copies/mL) post-ZIKV challenge. Each line represents an individual macaque." exact="Zika" post="vRNA levels below the LLOQ are plotted as half"/>
  <result pre="an anti-Zika IgG response which correlated with a reduction in" exact="ZIKV" post="vRNA post-challenge (Table 2). An immune correlate analysis was"/>
  <result pre="2). An immune correlate analysis was subsequently performed to correlate" exact="Zika" post="vRNA with neutralizing antibody titers (Fig. 4) and anti-Zika"/>
  <result pre="antibody titer of &amp;gt;3.02 log10 EC50, which conferred protection against" exact="ZIKV" post="serum viremia in Indian rhesus macaques. Due to overlap"/>
  <result pre="of protection. Table 2 Neutralizing antibody titers on day of" exact="ZIKV" post="challenge, Zika vRNA levels post-challenge. PIZV dose (µg) Mean"/>
  <result pre="Table 2 Neutralizing antibody titers on day of ZIKV challenge," exact="Zika" post="vRNA levels post-challenge. PIZV dose (µg) Mean neutralizing antibody"/>
  <result pre="neutralizing antibody titer (log10 EC50), day 71 Range of peak" exact="Zika" post="vRNA detection (log10 copies/mL) Percent macaques protected from ZIKV"/>
  <result pre="peak Zika vRNA detection (log10 copies/mL) Percent macaques protected from" exact="ZIKV" post="challenge 0 1.33 4.92–5.64 0 0.016 2.63 4.10–5.00 33"/>
  <result pre="post-ZIKV challenge (log10 copies/mL), and percent of macaques with quantifiable" exact="Zika" post="vRNA post-ZIKV challenge. All reported and analyzed data is"/>
  <result pre="of quantitation. Figure 4 Neutralizing antibody titers negatively correlate with" exact="Zika" post="vRNA peak value post-challenge. (a) Each point represents an"/>
  <result pre="and respective neutralizing antibody titer (log10 EC50) on day of" exact="ZIKV" post="challenge (day 71) and peak ZIKV vRNA concentration (log10"/>
  <result pre="EC50) on day of ZIKV challenge (day 71) and peak" exact="ZIKV" post="vRNA concentration (log10 copies/mL) post-ZIKV challenge. For each macaque,"/>
  <result pre="concentration (log10 copies/mL) post-ZIKV challenge. For each macaque, the maximum" exact="Zika" post="vRNA concentration observed over 10 days was plotted for"/>
  <result pre="vRNA concentration observed over 10 days was plotted for analysis." exact="Zika" post="vRNA levels below the LLOQ are plotted as half"/>
  <result pre="protection. Figure 5 Anti-Zika IgG antibody titers negatively correlate with" exact="Zika" post="vRNA post-challenge. (a) Each point represents an individual macaque."/>
  <result pre="Day 71 anti-Zika IgG and the peak vRNA concentration following" exact="ZIKV" post="challenge. Zika vRNA values below the LLOQ were replaced"/>
  <result pre="anti-Zika IgG and the peak vRNA concentration following ZIKV challenge." exact="Zika" post="vRNA values below the LLOQ were replaced by half"/>
  <result pre="PIZV on study days 1 and 29 and challenged with" exact="ZIKV" post="PRVABC59 on study day 371. Zika neutralizing antibody levels"/>
  <result pre="29 and challenged with ZIKV PRVABC59 on study day 371." exact="Zika" post="neutralizing antibody levels were measured every 28 days through"/>
  <result pre="through study day 365 (Fig. 6b). IgG titers increased following" exact="ZIKV" post="challenge. Figure 6 Long-term immunogenicity following PIZV vaccination. Both"/>
  <result pre="day 57 (28 days post-second dose), day 365 (prior to" exact="ZIKV" post="challenge), and day 401 (30 days post-ZIKV challenge). Each"/>
  <result pre="days post-ZIKV challenge). Each line represents an individual macaque. No" exact="Zika" post="vRNA was detected in serum from any of the"/>
  <result pre="was detected in serum from any of the macaques following" exact="ZIKV" post="challenge 1 year following the second dose. In addition,"/>
  <result pre="The combined results suggest that two doses of PIZV prevented" exact="ZIKV" post="infection 1 year post-vaccination. In conclusion, two 10 µg PIZV"/>
  <result pre="We demonstrated that PIZV elicits a dose-dependent response of both" exact="Zika" post="neutralizing and anti-Zika IgG antibodies. PIZV elicited neutralizing antibodies"/>
  <result pre="that persisted for at least 1 year and protected against" exact="ZIKV" post="challenge. Vaccinating with a broad range of PIZV dose"/>
  <result pre="both neutralizing and anti-Zika IgG antibody titers to protection against" exact="ZIKV" post="infection. We determined a neutralizing antibody correlate of protection"/>
  <result pre="using functional neutralizing antibodies as a correlate of protection for" exact="Zika" post="and other flaviviruses. Neutralizing antibodies directed against the envelope"/>
  <result pre="induction of ZIKV-specific neutralizing antibodies that conferred protection against live" exact="ZIKV" post="challenge in animal models6–8,16–22. These data support ZIKV E-specific"/>
  <result pre="against live ZIKV challenge in animal models6–8,16–22. These data support" exact="ZIKV" post="E-specific neutralizing antibodies as a mechanism of protection against"/>
  <result pre="ZIKV E-specific neutralizing antibodies as a mechanism of protection against" exact="ZIKV" post="infection. In flavivirus vaccine development, neutralizing antibody titers that"/>
  <result pre="RVP, and plaque reduction neutralization (PRNT). Studies of other candidate" exact="ZIKV" post="vaccines have demonstrated that a neutralizing antibody titer as"/>
  <result pre="of protection, it has been reported that passive transfer of" exact="Zika" post="neutralizing monoclonal antibodies or antisera from vaccinated humans and"/>
  <result pre="humans and animals to mice is sufficient to protect against" exact="ZIKV" post="challenge16,17,21,26. Adoptive transfer of serum from immunized mice fully"/>
  <result pre="provided marginal protection27 demonstrating that the mechanism of protection against" exact="ZIKV" post="infection is antibody mediated. While ZIKV exists as three"/>
  <result pre="mechanism of protection against ZIKV infection is antibody mediated. While" exact="ZIKV" post="exists as three genotypes (West African, East African and"/>
  <result pre="capable of eliciting antibodies that neutralize both African and Asian" exact="ZIKV" post="isolates in vitro16. Others have shown that the magnitude"/>
  <result pre="magnitude or duration of viremia in unvaccinated macaques challenged with" exact="ZIKV" post="isolates from Brazil or Puerto Rico is similar6, and"/>
  <result pre="and that vaccinated macaques are protected against challenge with heterologous" exact="ZIKV" post="strains13,21,30. Protection of animal models against heterologous challenge and"/>
  <result pre="challenge strain may be sufficient to show cross protection against" exact="ZIKV" post="strains from other lineages. Several groups have developed rhesus"/>
  <result pre="lineages. Several groups have developed rhesus macaque challenge models using" exact="Zika" post="strain PRVABC596,7,9,12,31 which is a well-documented and characterized isolate"/>
  <result pre="PIZV efficacy in mice16 to demonstrate efficacy in prevention of" exact="ZIKV" post="vRNA and to evaluate anamnestic antibody responses after ZIKV"/>
  <result pre="of ZIKV vRNA and to evaluate anamnestic antibody responses after" exact="ZIKV" post="challenge in non-human primates. We did not assess presence"/>
  <result pre="in tissues. Our working hypothesis is that prevention of serum" exact="ZIKV" post="vRNA may be a surrogate for prevention of the"/>
  <result pre="a surrogate for prevention of the most serious sequelae of" exact="ZIKV" post="infection in humans - fetal infection. By employing a"/>
  <result pre="By employing a PIZV dose titration study design and a" exact="ZIKV" post="RVP assay, we have established a minimum protective vaccine"/>
  <result pre="macaques and established a neutralizing antibody correlate of protection against" exact="ZIKV" post="challenge of 3.02 log10 EC50. Finally, we demonstrated that"/>
  <result pre="ZIKV challenge of 3.02 log10 EC50. Finally, we demonstrated that" exact="ZIKV" post="neutralizing antibodies persist and are capable of preventing ZIKV"/>
  <result pre="that ZIKV neutralizing antibodies persist and are capable of preventing" exact="ZIKV" post="infection for at least 1 year post-vaccination. In the"/>
  <result pre="challenge model may be important to support licensure of a" exact="Zika" post="vaccine3,5,32. Altogether, these data support neutralizing antibodies as an"/>
  <result pre="aluminum hydroxide adjuvanted whole purified inactivated virus vaccine based on" exact="ZIKV" post="strain PRVABC59 which was originally isolated from serum from"/>
  <result pre="from the control group was euthanized on the day of" exact="ZIKV" post="challenge due to reasons unrelated to the study, resulting"/>
  <result pre="the control group. Macaques were challenged subcutaneously with 104 ffu/0.5 mL" exact="ZIKV" post="PRVABC59 on study day 71. Serum samples were collected"/>
  <result pre="days 1, 29, 57, and 71, and 101, and for" exact="ZIKV" post="RNA on study days 71–80, and study day 84."/>
  <result pre="days 1 and 29 and challenged subcutaneously with 104 ffu/0.5 mL" exact="ZIKV" post="PRVABC59 on day 371. Serum samples were collected and"/>
  <result pre="monthly up to 1 year post-vaccination and 30 days following" exact="ZIKV" post="challenge (study day 401). To assess replication of Zika"/>
  <result pre="following ZIKV challenge (study day 401). To assess replication of" exact="Zika" post="vRNA following ZIKV challenge, serum samples were collected on"/>
  <result pre="(study day 401). To assess replication of Zika vRNA following" exact="ZIKV" post="challenge, serum samples were collected on study days 371–381,"/>
  <result pre="were collected on study days 371–381, and 385. Challenge virus" exact="Zika" post="virus Puerto Rico strain PRVABC59 was used for the"/>
  <result pre="magnetic beads coupled with Zika, Dengue, Yellow Fever, Japanese Encephalitis," exact="West Nile," post="Usutu, Saint Louis Encephalitis, and Chikungunya virus antigens. Serum"/>
  <result pre="Fever, Japanese Encephalitis, West Nile, Usutu, Saint Louis Encephalitis, and" exact="Chikungunya" post="virus antigens. Serum and beads were incubated on a"/>
  <result pre="cutoff criteria for seronegativity for all antigens. Neutralizing antibodies A" exact="Zika" post="RVP assay (Sonnberg et al., manuscript in preparation) was"/>
  <result pre="for study days 1, 29, 57, and 71 (prior to" exact="ZIKV" post="challenge) using a Luminex based anti-Zika IgG assay. Heat-inactivated"/>
  <result pre="purified RNA was evaluated in two separate RT-PCR assays. Primarily," exact="Zika" post="vRNA was detected and quantified using RT-qPCR with primers"/>
  <result pre="quantified using RT-qPCR with primers and probe specific to known" exact="ZIKV" post="genotypes as described in Lanciotti et al.33 and a"/>
  <result pre="et al.33 and a standard curve generated from synthetic reference" exact="Zika" post="vRNA (ATCC). A qualitative extraction control RT-PCR was also"/>
  <result pre="confirmed adequate nucleic acid extraction from serum samples independent of" exact="Zika" post="vRNA detection. The geometric mean, range of peak Zika"/>
  <result pre="of Zika vRNA detection. The geometric mean, range of peak" exact="Zika" post="vRNA detection, and the respective percentage of protected macaques"/>
  <result pre="protection The mean neutralizing antibody titers (log10 EC50) determined by" exact="Zika" post="RVP assay was computed for each dose group at"/>
  <result pre="computed for each dose group at day 71 (day of" exact="ZIKV" post="challenge). Zika vRNA copies/mL determined by RT-qPCR assay were"/>
  <result pre="each dose group at day 71 (day of ZIKV challenge)." exact="Zika" post="vRNA copies/mL determined by RT-qPCR assay were computed for"/>
  <result pre="Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with Congenital" exact="Zika" post="Virus Infection - U.S. Territories and Freely Associated States,"/>
  <result pre="Organization. PLISA Health Information Platform for the Americas: Cases of" exact="Zika" post="virus disease, by country or territory, http://www.paho.org/data/index.php/en/mnu-topics/zika/524-zika-weekly-en.html (Accessed 27Aug2019)."/>
  <result pre="http://www.paho.org/data/index.php/en/mnu-topics/zika/524-zika-weekly-en.html (Accessed 27Aug2019). 3.GruberMFet al.Clinical Development Strategies and Considerations for" exact="Zika" post="Vaccine LicensureJ. Infect. Dis.2017216S964S97010.1093/infdis/jix43329267913 4.PlotkinSACorrelates of protection induced by"/>
  <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 6.AbbinkPet al.Protective efficacy of multiple vaccine platforms"/>
  <result pre="vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 6.AbbinkPet al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysSci.20163531129113210.1126/science.aah6157 7.DowdKAet al.Rapid development of"/>
  <result pre="rhesus monkeysSci.20163531129113210.1126/science.aah6157 7.DowdKAet al.Rapid development of a DNA vaccine for" exact="Zika" post="virusSci.201635423724010.1126/science.aai9137 8.RichnerJMet al.Modified mRNA Vaccines Protect against Zika Virus"/>
  <result pre="vaccine for Zika virusSci.201635423724010.1126/science.aai9137 8.RichnerJMet al.Modified mRNA Vaccines Protect against" exact="Zika" post="Virus InfectionCell201716917610.1016/j.cell.2017.03.01628340344 9.RaynerJonathanKalkeriRajGoebelScottCaiZhaohuiGreenBrianLinShulingSnyderBethHagelinKimberlyWaltersKevinKoideFusatakaComparative Pathogenesis of Asian and African-Lineage Zika"/>
  <result pre="against Zika Virus InfectionCell201716917610.1016/j.cell.2017.03.01628340344 9.RaynerJonathanKalkeriRajGoebelScottCaiZhaohuiGreenBrianLinShulingSnyderBethHagelinKimberlyWaltersKevinKoideFusatakaComparative Pathogenesis of Asian and African-Lineage" exact="Zika" post="Virus in Indian Rhesus Macaque’s and Development of a"/>
  <result pre="Evaluation of New Drugs and VaccinesViruses201810522910.3390/v10050229 10.OsunaCEWhitneyJBNonhuman Primate Models of" exact="Zika" post="Virus Infection, Immunity, and Therapeutic DevelopmentJ. Infect. Dis.2017216S928S93410.1093/infdis/jix54029267926 11.NewmanCFriedrichTCO’ConnorDHMacaque"/>
  <result pre="Infection, Immunity, and Therapeutic DevelopmentJ. Infect. Dis.2017216S928S93410.1093/infdis/jix54029267926 11.NewmanCFriedrichTCO’ConnorDHMacaque monkeys in" exact="Zika" post="virus research: 1947-presentCurr. Opin. Virol.201725344010.1016/j.coviro.2017.06.01128750247 12.LiXFet al.Characterization of a"/>
  <result pre="Opin. Virol.201725344010.1016/j.coviro.2017.06.01128750247 12.LiXFet al.Characterization of a 2016 Clinical Isolate of" exact="Zika" post="Virus in Non-human PrimatesEBioMedicine20161217017710.1016/j.ebiom.2016.09.02227693104 13.AliotaMTet al.Heterologous Protection against Asian"/>
  <result pre="Zika Virus in Non-human PrimatesEBioMedicine20161217017710.1016/j.ebiom.2016.09.02227693104 13.AliotaMTet al.Heterologous Protection against Asian" exact="Zika" post="Virus Challenge in Rhesus MacaquesPLoS Negl. Trop. Dis.201610e000516810.1371/journal.pntd.000516827911897 14.DudleyDMet"/>
  <result pre="Negl. Trop. Dis.201610e000516810.1371/journal.pntd.000516827911897 14.DudleyDMet al.A rhesus macaque model of Asian-lineage" exact="Zika" post="virus infectionNat. Commun.201671220410.1038/ncomms1220427352279 15.HirschAJet al.Zika Virus infection of rhesus"/>
  <result pre="to viral persistence in multiple tissuesPLoS Pathog.201713e100621910.1371/journal.ppat.100621928278237 16.BaldwinWRet al.Purified Inactivated" exact="Zika" post="Vaccine Candidates Afford Protection against Lethal Challenge in MiceSci."/>
  <result pre="against Lethal Challenge in MiceSci. Rep.201881650910.1038/s41598-018-34735-730405178 17.SumathyKet al.Protective efficacy of" exact="Zika" post="vaccine in AG129 mouse modelSci. Rep.201774637510.1038/srep4637528401907 18.PardiNet al.Zika virus"/>
  <result pre="single low-dose nucleoside-modified mRNA vaccinationNat.201754324825110.1038/nature21428 19.MuthumaniKet al.In vivo protection against" exact="ZIKV" post="infection and pathogenesis through passive antibody transfer and active"/>
  <result pre="with a prMEnv DNA vaccineNPJ Vaccines201611602110.1038/npjvaccines.2016.2129263859 20.LaroccaRAet al.Vaccine protection against" exact="Zika" post="virus from BrazilNat.201653647447810.1038/nature18952 21.AbbinkPeterLaroccaRafael A.VisitsunthornKittiposBoydMichaelDe La BarreraRafael A.GromowskiGregory D.KirilovaMarinelaPetersonRebeccaLiZhenfengNanayakkaraOviniNityanandamRamyaMercadoNoe"/>
  <result pre="H.ThomasStephen J.MichaelNelson L.BarouchDan H.Durability and correlates of vaccine protection against" exact="Zika" post="virus in rhesus monkeysScience Translational Medicine20179420eaao416310.1126/scitranslmed.aao416329237759 22.EspinosaDet al.Passive Transfer"/>
  <result pre="Medicine20179420eaao416310.1126/scitranslmed.aao416329237759 22.EspinosaDet al.Passive Transfer of Immune Sera Induced by a" exact="Zika" post="Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika"/>
  <result pre="a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal" exact="Zika" post="Virus ChallengeEBioMedicine201827617010.1016/j.ebiom.2017.12.01029269041 23.HombachJSolomonTKuraneIJacobsonJWoodDReport on a WHO consultation on immunological"/>
  <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
  <result pre="randomised, double-blind, placebo-controlled clinical trialsLancet201839156357110.1016/S0140-6736(17)33106-929217375 27.NazeraiLoulietaPravsgaard ChristensenJanRandrup ThomsenAllanA ‘Furry-Tale’ of" exact="Zika" post="Virus Infection: What Have We Learned from Animal Models?Viruses20191112910.3390/v11010029"/>
  <result pre="What Have We Learned from Animal Models?Viruses20191112910.3390/v11010029 28.LanciottiRSLambertAJHolodniyMSaavedraSSignor LdelCPhylogeny of" exact="Zika" post="Virus in Western Hemisphere, 2015Emerg. Infect. Dis.20162293393510.3201/eid2205.16006527088323 29.DowdKAet al.Broadly"/>
  <result pre="Western Hemisphere, 2015Emerg. Infect. Dis.20162293393510.3201/eid2205.16006527088323 29.DowdKAet al.Broadly Neutralizing Activity of" exact="Zika" post="Virus-Immune Sera Identifies a Single Viral SerotypeCell Rep.2016161485149110.1016/j.celrep.2016.07.04927481466 30.SariolCANogueiraMLVasilakisNA"/>
  <result pre="30.SariolCANogueiraMLVasilakisNA Tale of Two Viruses: Does Heterologous Flavivirus Immunity Enhance" exact="Zika" post="Disease?Trends Microbiol.20182618619010.1016/j.tim.2017.10.00429122447 31.OsunaCEet al.Zika viral dynamics and shedding in"/>
  <result pre="Harbor Perspectives in Biology2017104a02890210.1101/cshperspect.a028902 33.LanciottiRSet al.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007Emerg."/>
 </snippets>
</snippetsTree>
